Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2024 Filed Nov 22, 2024 21:23 UTC |
Drexler KarenDirector
|
GrantResMed Common Stock | 1,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-027903 · form4.xml · nonDerivative · entry 1 Drexler Karen · CIK 0001504699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,529 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2025, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:22 UTC |
De Witte JanDirector
|
GrantReMed Common Stock | 1,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-027902 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,806 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2025, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:21 UTC |
Hernandez JohnDirector
|
GrantResMed Common Stock | 1,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-027901 · form4.xml · nonDerivative · entry 1 Hernandez John · CIK 0001890555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,045 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2025, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:20 UTC |
Gill HarjitDirector
|
GrantResMed Common Stock | 1,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-027900 · form4.xml · nonDerivative · entry 1 Gill Harjit · CIK 0001759311 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,905 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2025, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:19 UTC |
DelOrefice ChristopherDirector
|
GrantResMed Common Stock | 1,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-027899 · form4.xml · nonDerivative · entry 1 DelOrefice Christopher · CIK 0001881430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,350 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2025, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:18 UTC |
Burt CarolDirector
|
GrantResMed Common Stock | 1,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-027898 · form4.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,851 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2025, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:01 UTC |
FARRELL PETER CDirector
|
GrantResMed Common Stock | 542 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-027893 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,218 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2025, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 16:49 UTC |
De Witte JanDirector
|
SaleReMed Common Stock | 796 | $248.81 | $198,052.76 |
DisclosureSEC source: 0001127602-24-027277 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,723 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 2, 2024. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 23:01 UTC |
FARRELL PETER CDirector
|
Tax withholdingResMed Common Stock | 527.905 | $252.38 | $133,232.66 |
DisclosureSEC source: 0001127602-24-027102 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,676 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:57 UTC |
Gill HarjitDirector
|
Tax withholdingResMed Common Stock | 132.601 | $252.38 | $33,465.84 |
DisclosureSEC source: 0001127602-24-027099 · form4.xml · nonDerivative · entry 1 Gill Harjit · CIK 0001759311 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,822 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:45 UTC |
Rider Michael JGlobal General Counsel
|
Tax withholdingResMed Common Stock | 136.837 | $252.38 | $34,534.92 |
DisclosureSEC source: 0001127602-24-027092 · form4.xml · nonDerivative · entry 4 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,360 F4 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/19/2020. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:45 UTC |
Rider Michael JGlobal General Counsel
|
Tax withholdingResMed Common Stock | 172.312 | $252.38 | $43,488.10 |
DisclosureSEC source: 0001127602-24-027092 · form4.xml · nonDerivative · entry 3 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,497 F3 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:45 UTC |
Rider Michael JGlobal General Counsel
|
Tax withholdingResMed Common Stock | 134.303 | $252.38 | $33,895.39 |
DisclosureSEC source: 0001127602-24-027092 · form4.xml · nonDerivative · entry 2 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,669 F2 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/18/2021. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:45 UTC |
Rider Michael JGlobal General Counsel
|
Tax withholdingResMed Common Stock | 684.979 | $252.38 | $172,875.00 |
DisclosureSEC source: 0001127602-24-027092 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,803 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:37 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 3,452.9 | $252.38 | $871,442.90 |
DisclosureSEC source: 0001127602-24-027086 · form4.xml · nonDerivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,472 F7 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:37 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 2,226.863 | $252.38 | $562,015.68 |
DisclosureSEC source: 0001127602-24-027086 · form4.xml · nonDerivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 458,925 F6 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:37 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 3,101.376 | $252.38 | $782,725.27 |
DisclosureSEC source: 0001127602-24-027086 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,152 F5 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/18/2021. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:25 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Tax withholdingResMed Common Stock | 1,417.925 | $252.38 | $357,855.91 |
DisclosureSEC source: 0001127602-24-027070 · form4.xml · nonDerivative · entry 3 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,725 F3 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:25 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Tax withholdingResMed Common Stock | 445.588 | $252.38 | $112,457.50 |
DisclosureSEC source: 0001127602-24-027070 · form4.xml · nonDerivative · entry 2 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,142 F2 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:25 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Tax withholdingResMed Common Stock | 603.075 | $252.38 | $152,204.07 |
DisclosureSEC source: 0001127602-24-027070 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,588 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/18/2021. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:33 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,000 | $249.00 | $249,000.00 |
DisclosureSEC source: 0001127602-24-027030 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,864 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. F2 · balance_after: Includes 51.807 shares of ResMed stock purchased on October 31, 2024, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 22:37 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 14,683 | $0.00 Strike: $84.98 | $0.00 |
DisclosureSEC source: 0001127602-24-027086 · form4.xml · derivative · entry 7 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 14,683 shares Expires 2024-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024. F9 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 22:37 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 14,683 | $246.26 | $3,615,820.90 |
DisclosureSEC source: 0001127602-24-027086 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 464,254 F3 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $244.74 - $248.38 The price reported above reflects the weighted average sale price. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 22:37 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 14,683 | $84.98 | $1,247,761.34 |
DisclosureSEC source: 0001127602-24-027086 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 478,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024. F2 · balance_after: Includes 84.129 shares of ResMed stock purchased on October 31, 2024, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 18:15 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 2,000 | $248.74 | $497,480.00 |
DisclosureSEC source: 0001127602-24-026799 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,204 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 17:20 UTC |
Rider Michael JGlobal General Counsel
|
SaleResMed Common Stock | 69 | $242.00 | $16,698.00 |
DisclosureSEC source: 0001127602-24-026442 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,443 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 11, 2024. Read SEC document |
| October 30, 2024 Filed Nov 2, 2024 00:07 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
OtherResMed Common Stock | 9,628.096 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-026257 · form4.xml · nonDerivative · entry 2 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: No plan indicated Ownership: Indirect · Kaushik Ghoshal and Jayati Ghoshal Family Trust Disclosed balance after: 9,628 Read SEC document |
| October 30, 2024 Filed Nov 2, 2024 00:07 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
OtherResMed Common Stock | 9,628.096 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-026257 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,160 F1 · kind: Transfer of shares from direct holdings to the Kaushik Ghoshal and Jayati Ghoshal Family Trust. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 14:06 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,260 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001127602-24-025433 · form4.xml · derivative · entry 3 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 4,260 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 14:06 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
SaleResMed Common Stock | 4,260 | $238.48 | $1,015,924.80 |
DisclosureSEC source: 0001127602-24-025433 · form4.xml · nonDerivative · entry 2 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,788 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted April 29, 2024. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 14:06 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock | 4,260 | $101.64 | $432,986.40 |
DisclosureSEC source: 0001127602-24-025433 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted April 29, 2024. Read SEC document |
| October 08, 2024 Filed Oct 9, 2024 20:38 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,000 | $233.47 | $233,470.00 |
DisclosureSEC source: 0001127602-24-025369 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,812 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 17:44 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 14,683 | $0.00 Strike: $84.98 | $0.00 |
DisclosureSEC source: 0001127602-24-025362 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,683 Underlying: ResMed Common Stock · 14,683 shares Expires 2024-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 17:44 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 14,683 | $231.91 | $3,405,206.48 |
DisclosureSEC source: 0001127602-24-025362 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 464,169 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $230.66 - $234.70 The price reported above reflects the weighted average sale price. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 17:44 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 14,683 | $84.98 | $1,247,761.34 |
DisclosureSEC source: 0001127602-24-025362 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 478,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024. Read SEC document |
| October 02, 2024 Filed Oct 2, 2024 20:20 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 2,000 | $237.20 | $474,400.00 |
DisclosureSEC source: 0001127602-24-024898 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,204 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 18:54 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,000 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001127602-24-023884 · form4.xml · derivative · entry 3 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,260 Underlying: ResMed Common Stock · 5,000 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 18:54 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
SaleResMed Common Stock | 5,000 | $252.56 | $1,262,800.00 |
DisclosureSEC source: 0001127602-24-023884 · form4.xml · nonDerivative · entry 2 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,788 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted April 29, 2024. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 18:54 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock | 5,000 | $101.64 | $508,200.00 |
DisclosureSEC source: 0001127602-24-023884 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted April 29, 2024. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 01:18 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,000 | $246.42 | $246,420.00 |
DisclosureSEC source: 0001127602-24-023758 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,812 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 01:11 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 14,683 | $0.00 Strike: $84.98 | $0.00 |
DisclosureSEC source: 0001127602-24-023757 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,366 Underlying: ResMed Common Stock · 14,683 shares Expires 2024-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 01:11 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 14,683 | $248.38 | $3,646,950.33 |
DisclosureSEC source: 0001127602-24-023757 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 464,169 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $245.90 - $254.06. The price reported above reflects the weighted average sale price. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 01:11 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 14,683 | $84.98 | $1,247,761.34 |
DisclosureSEC source: 0001127602-24-023757 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 478,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024. Read SEC document |
| September 04, 2024 Filed Sep 6, 2024 19:01 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 2,000 | $239.90 | $479,800.00 |
DisclosureSEC source: 0001127602-24-023609 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,204 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 22:30 UTC |
DelOrefice ChristopherDirector
|
GrantResMed Common Stock | 267 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-023595 · form4.xml · nonDerivative · entry 1 DelOrefice Christopher · CIK 0001881430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the first anniversary of the grant date. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 18:29 UTC |
Rider Michael JGlobal General Counsel
|
SaleResMed Common Stock | 882 | $231.00 | $203,742.00 |
DisclosureSEC source: 0001127602-24-022691 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,512 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 11, 2024. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 14:21 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 841 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-022304 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,812 F2 · kind: Represents performance-based restricted stock units granted on November 16, 2023. The shares were earned on August 15, 2024, when the compensation committee certified that the performance metrics were met for this portion ofthegrant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 14:21 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 7,915 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-022304 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,971 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2023. The shares were earned on August 15, 2024, when the compensation committee certified that the performance metrics were met. Stock unitsvest1/3each year on the anniversary of the grant. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 14:19 UTC |
Rider Michael JGlobal General Counsel
|
GrantResMed Common Stock | 476 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-022302 · form4.xml · nonDerivative · entry 2 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,394 F2 · kind: Represents performance-based restricted stock units granted on November 16, 2023. The shares were earned on August 15, 2024, when the compensation committee certified that the performance metrics were met for this portion ofthegrant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 14:19 UTC |
Rider Michael JGlobal General Counsel
|
GrantResMed Common Stock | 4,474 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-022302 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,918 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2023. The shares were earned on August 15, 2024, when the compensation committee certified that the performance metrics were met. Stock units vest1/3each year on the anniversary of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.